Thought Leadership
Ranbaxy Loses Bid to Block Other Firms' Nexium, Valcyte Generic Products
March 2, 2015
Dana Elfin
Bloomberg BNA Pharmaceutical Law & Industry Report

Axinn Partner Chad Landmon was quoted in the Bloomberg BNA Pharmaceutical Law & Industry Report article, "Ranbaxy Loses Bid to Block Other Firms' Nexium, Valcyte Generic Products."

Click here to access the Bloomberg BNA Pharmaceutical Law & Industry Report. A subscription is required.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.